Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
7 NC counties are under alert, including Johnston County.
Program
On WRAL at 6: Hidden fees in your childâs school lunch payment ð¨ð¸ 5 On Your Side shows you how to keep more money in your pocket
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bridgebio Pharma Inc
(NQ:
BBIO
)
25.66
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bridgebio Pharma Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Rare Disease Player BridgeBio Pharma's Upside Potential Is Significant According to Citi Analyst - Here's Why
November 07, 2023
Citi initiated coverage on BridgeBio Pharma Inc (NASDAQ: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, noting an optimistic outlook on the stock.
Via
Benzinga
BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update
November 02, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
The Latest Analyst Ratings for BridgeBio Pharma
October 24, 2023
Via
Benzinga
BridgeBio Pharma Inc. (NASDAQ: BBIO) is a Stock Spotlight on 8/18
August 18, 2023
Via
Investor Brand Network
4 Analysts Have This to Say About BridgeBio Pharma
August 14, 2023
Via
Benzinga
Why BridgeBio Pharma Was a Healthy Stock Today
October 24, 2023
One of the best-performing biotechs on the stock market this year gets a bullish nod from a researcher.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
October 24, 2023
Via
Benzinga
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
October 10, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
October 09, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
October 03, 2023
From
National Resilience, Inc.
Via
Business Wire
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
October 03, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty
September 28, 2023
Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 28, 2023
Via
Benzinga
BridgeBio Pharma Announces $250 Million Private Placement Equity Financing
September 25, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates
September 13, 2023
These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments.
Via
InvestorPlace
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 07, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
September 06, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
What's Going On With BridgeBio Pharma Stock Today?
August 28, 2023
BridgeBio Pharma Inc (NASDAQ: BBIO) announced the presentation of detailed results from its Phase 3 ATTRibute-CM study of acoramidis for ATTR-CM at the
Via
Benzinga
Pfizer Was First In Treating This Heart Disease. Why BridgeBio Could Be Better.
August 28, 2023
The companies are expected to compete in a genetic heart disease beginning in late 2024.
Via
Investor's Business Daily
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
August 27, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023
August 24, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It?
August 09, 2023
Its potential upcoming drug launch might not be enough.
Via
The Motley Fool
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update
August 03, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
7 A-Rated Stocks for Your August Buy List
August 03, 2023
August is shaping up to be a great month for the stock market. Now you just need to make sure you own these A-rated stocks.
Via
InvestorPlace
BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study
July 31, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Could This Stock Be the Next Biotech Buyout?
July 31, 2023
A buyout deal recently pushed Reata Pharmaceuticals stock 53% higher in a single trading session, leading investors to wonder who's next.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.